VICTORIA, Feb. 5, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced the purchase of its second state-of-the-art Intellicyt® iQue Screener PLUS for high-throughput cell-based screening.
The demand for accelerated development of next-generation antibodies that recognize evermore challenging targets and have improved activities has prompted IPA to purchase further instrumentation to evaluate more antibody characteristics in a multiplexed, high-throughput way. Traditional antibody screening tools report on binding one target at a time, which makes the discovery process time consuming and can require large amounts of target protein. The Intellicyt iQue allows IPA scientists to significantly reduce lead discovery time while conserving valuable samples and reducing reagent cost.
"The decision to acquire a second Intellicyt iQue [now for North America] will further support IPA's strategic vision of continued growth and expansion in providing end-to-end therapeutic antibody discovery services to a rapidly expanding list of pharma and biotech clients." said Jennifer Bath, CEO and President of ImmunoPrecise Antibodies.
The iQue Screener PLUS can analyze antibodies developed from all of IPA's antibody discovery platforms, hybridoma, B cell select, and phage display, on cells or beads in suspension. The early stage screening of antibodies on cell surface targets provides more predictable data and enables the selection of lead candidate drugs earlier and faster. In addition, the iQue provides early data on the activities of lead drugs to improve the probability for downstream successes.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic and diagnostic antibody discovery company focused on the next generation of antibody discovery, to deliver the most relevant antibodies, in a shorter period of time, with the highest probability of succeeding through clinical validation.
ImmunoPrecise Antibodies Ltd operates from three state-of-the-art laboratory facilities. ImmunoPrecise Antibodies (Canada) is located in Victoria, British Columbia, while U-Protein Express B.V., and ModiQuest Research B.V. are located in Utrecht and Oss, Netherlands, respectively. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.
The services offered to clients include antibody discovery for a broad spectrum of antigens, including challenging targets. Among these services, the Company offers antibody development directly from B-cells (B-Cell Select), through phage display, and by hybridoma production. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend" and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the fiscal year ended April 30, 2017 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.
View original content: http://www.newswire.ca/en/releases/archive/February2019/05/c8386.html
